“Injecting in a different spot changes how well it works.”
What the evidence shows
This is settled by the FDA label. Semaglutide is injected under the skin (subcutaneously) in the abdomen, thigh, or upper arm, and the Wegovy label states plainly that 'the time of day and the injection site can be changed without the need for a dosage modification.' The label recommends rotating sites with each dose — standard practice for any subcutaneous injection to spare the skin — but that rotation is for skin comfort, not because one area makes the medicine work better than another.
What we still don’t know
There's no consumer-relevant evidence that choosing the belly over the thigh or arm changes the weight or blood-sugar effect of a once-weekly GLP-1, whose long duration of action smooths out any tiny site-to-site differences in absorption. Injection technique still matters in the ordinary ways (correct subcutaneous placement, clean skin), which is covered in the product's instructions and by the prescriber.
Why the claim misleads
'A different spot changes how well it works' invents a variable the label explicitly rules out. Rotating sites is about protecting the skin from repeated jabs, not about chasing better results. Picking whichever approved site is convenient is fine; the real guardrails are using an approved area, rotating, and following the product instructions — details to confirm with a clinician or pharmacist, not something that secretly makes or breaks the dose.
Graded by The Peptide Era · evidence, not hype